Similar results were also reported for AZD5363 [29], although exclusive PIK3CA mutations did not correlate with increased response in another study in breast or gynecological cancer patients where concurrent mutations in KRAS, NRAS, HRAS, or BRAF were excluded [23]. This evidence concerns the gene HRAS and female reproductive organ cancer.